mufa 16:1 c

MUFA 16:1 c refers to the cis-configured 16:1 monounsaturated fatty acid known chemically as palmitoleic acid or cis-9-hexadecenoic acid. This molecule has 16 carbon atoms with a single double bond in the cis configuration at the ninth carbon from the carboxyl end, classifying it as a monounsaturated fatty acid (MUFA). MUFAs are characterized by the presence of one double bond in their carbon chain, distinguishing them from saturated fatty acids with no double bonds and polyunsaturated fatty acids (PUFAs) with multiple double bonds. In the context of human nutrition, MUFAs are dietary fats found in a variety of foods and are also synthesized endogenously in adipose tissue and liver through the action of enzymes such as stearoyl-CoA desaturase (SCD), which converts saturated fatty acids like palmitic acid into MUFAs such as palmitoleic acid. Palmitoleic acid has garnered attention as an "omega-7" fatty acid, indicating the position of the double bond relative to the methyl (omega) end of the carbon chain, which contrasts with other MUFAs like oleic acid (omega-9). The cis isomer (16:1 c) is the naturally occurring form found in many foods and tissues, whereas the trans isomer (often termed trans-palmitoleic acid) is associated with dairy fat intake and has been studied for its potential associations with metabolic health. From a biochemical standpoint, MUFA 16:1 c integrates into triglycerides and cell membrane phospholipids, contributing to membrane fluidity and metabolic flexibility. Although total MUFAs are a component of dietary fat intake, palmitoleic acid specifically comprises a smaller fraction compared to more abundant MUFAs like oleic acid. Because palmitoleic acid can be produced endogenously, it does not have an official essential nutrient classification with a defined recommended dietary allowance (RDA) or adequate intake (AI) set by authoritative bodies such as the NIH Office of Dietary Supplements. Instead, dietary intake contributes to circulating levels, and metabolism tightly regulates endogenous synthesis. The term "lipokine" has been used to describe palmitoleic acid’s role as a lipid signaling molecule, suggesting it may coordinate metabolic communication between adipose tissue and other organs. While some observational research has linked higher circulating palmitoleic acid with improved markers of insulin sensitivity and glucose tolerance in humans, results are mixed and further research is needed to fully elucidate its physiological roles and dietary requirements.

MUFA 16:1 c, or palmitoleic acid, participates in several biological processes extending beyond its structural role as a fatty acid. One of its primary functions is contributing to the composition and fluidity of cell membranes, which affects membrane-bound enzymes and receptor activities. Membrane fluidity is crucial in tissues with high metabolic demand, such as muscle and liver, where nutrient sensing and signal transduction efficiency can influence metabolic responses. A growing body of research characterizes palmitoleic acid as a "lipokine," a term used to describe lipid molecules that act similarly to hormones by conveying metabolic signals from adipose tissue to distant organs. Palmitoleic acid is released from adipose tissue and may interact with regulatory pathways controlling glucose uptake, insulin signaling, and lipid metabolism in skeletal muscle and liver. For instance, in observational studies, higher plasma palmitoleate concentrations have been independently associated with greater whole-body insulin sensitivity and improved glucose tolerance in non-diabetic adults, suggesting a beneficial role in maintaining glucose homeostasis. This association persisted after adjusting for confounding factors such as age, adiposity, and total non-esterified fatty acid levels, supporting the idea that endogenous palmitoleate contributes to metabolic regulation. In clinical cohorts, circulating palmitoleic acid has been linked to favorable beta cell function and a reduced decline in insulin sensitivity over time, potentially indicating a protective influence against the development of insulin resistance. In addition to metabolic effects, palmitoleic acid has displayed anti-inflammatory properties in cell culture and animal models. It appears capable of modulating the production of pro-inflammatory cytokines and attenuating inflammatory signaling pathways, which could have implications for chronic inflammatory conditions. For example, animal studies have shown that palmitoleic acid supplementation can reduce inflammation in liver and adipose tissues and alter gut microbiota composition in ways that enhance gut barrier function. By reducing local inflammation and supporting intestinal integrity, palmitoleic acid may indirectly influence systemic metabolic health. Some research also suggests potential effects on lipid profiles, including modest reductions in low-density lipoprotein (LDL) cholesterol and increases in high-density lipoprotein (HDL) cholesterol, though these findings are more robust for general MUFA-rich diets rather than palmitoleic acid alone. Despite these promising mechanistic insights and associations, evidence specific to palmitoleic acid is mixed in human studies, particularly regarding cardiovascular disease outcomes. Certain observational analyses have found associations between circulating palmitoleic acid and markers of dyslipidemia or obesity, indicating that its role in chronic disease may depend on broader metabolic context, including diet, adiposity, and genetic factors. Moreover, human intervention trials directly testing palmitoleic acid supplementation are limited, and while some small studies have used doses of cis-palmitoleic acid ranging from approximately 200 to 1,000 mg per day without major safety signals, the overall impact on inflammatory or metabolic biomarkers remains under investigation. Therefore, while palmitoleic acid participates in diverse metabolic processes and exhibits potential benefits related to insulin sensitivity, inflammation, and lipid metabolism, further high-quality human research is required to clarify its effects, optimal intake levels, and clinical utility.

Unlike essential vitamins and minerals, MUFA 16:1 c (palmitoleic acid) does not have an established recommended dietary allowance (RDA), adequate intake (AI), or tolerable upper intake level (UL) set by the NIH or other authoritative bodies. This lack of specific daily values reflects the fact that palmitoleic acid can be synthesized endogenously in humans via desaturation of palmitic acid catalyzed by stearoyl-CoA desaturase (SCD), and because it is not required for survival in the same way as essential nutrients. Consequently, dietary recommendations for palmitoleic acid are implicitly embedded within broader guidelines for total monounsaturated fat intake, which emphasize replacing saturated fats with unsaturated fats for cardiovascular health. From a macronutrient distribution perspective, total MUFAs typically comprise a significant proportion of dietary fat in healthy eating patterns. Diets such as the Mediterranean diet, which is rich in MUFA sources like olive oil, nuts, and fatty fish, often provide 15–25% of total energy from monounsaturated fatty acids. However, palmitoleic acid itself represents a smaller fraction of MUFA intake compared to oleic acid, the most abundant MUFA in most diets. Estimates indicate that average daily intake of palmitoleic acid in Western populations may be approximately 1.2 grams per day, with oleic acid contributing the lion’s share of MUFA intake. Because the body synthesizes palmitoleic acid endogenously, specific targets for intake have not been defined. Factors influencing endogenous palmitoleic acid levels include genetic variations affecting SCD activity, overall dietary fat composition, carbohydrate intake (which can stimulate de novo lipogenesis), and metabolic status. Carbohydrate-rich diets with excess calories may upregulate SCD-1 expression and increase palmitoleic acid synthesis independent of dietary intake. Additionally, adiposity and insulin resistance can influence circulating palmitoleate levels, potentially confounding dietary assessments. Therefore, while increasing intake of foods containing palmitoleic acid contributes to circulating levels, overall dietary patterns rich in unsaturated fats and low in saturated and trans fats are more informative for health guidance than focusing exclusively on palmitoleic acid intake. In research settings, supplemental palmitoleic acid doses have ranged from approximately 200–800 mg per day in small human trials, with some larger studies using 500–1,000 mg per day of concentrated omega-7 oil. However, because there are no established recommendations, such supplemental protocols are experimental and should be undertaken under clinical supervision. Until more conclusive evidence emerges, most dietary guidance emphasizes balanced fat intake within established dietary patterns rather than specific targets for MUFA 16:1 c.

Formal deficiency of MUFA 16:1 c, or palmitoleic acid, is not recognized in clinical nutrition because endogenous synthesis can compensate for low dietary intake. Unlike essential fatty acids such as linoleic acid and alpha-linolenic acid, palmitoleic acid is not required for survival and does not have a deficiency disease with a specific clinical name. That said, alterations in circulating palmitoleic acid levels have been studied as biomarkers of broader metabolic conditions. For instance, increased formation of palmitoleic acid in red blood cell lipids has been described as a marker of essential fatty acid deficiency, where heightened desaturation of palmitic acid occurs in response to limited intake of essential fats. In such contexts, elevated palmitoleic acid may signal compensatory metabolic changes rather than a standalone deficiency. Symptoms that might be associated with relative low intake of palmitoleic acid, rather than true deficiency, are nonspecific and reflect broader metabolic dysregulation rather than a unique clinical syndrome. Observational literature and expert commentaries suggest that inadequate dietary intake of MUFA-rich foods could correlate with unfavorable metabolic markers, such as increased LDL cholesterol, poorer insulin sensitivity, or higher inflammatory profiles, though these are not exclusive to palmitoleic acid and are influenced by overall diet quality. Factors such as high intake of saturated and trans fats, refined carbohydrates, and low consumption of unsaturated fats contribute to dyslipidemia, insulin resistance, and increased risk of chronic diseases such as type 2 diabetes and cardiovascular disease. At-risk populations for low MUFA 16:1 c status related to diet might include individuals consuming highly processed diets with limited sources of unsaturated fats. Vegetarians and vegans who do not consume animal sources of palmitoleic acid may rely entirely on plant-based sources like macadamia nuts and sea buckthorn oil for dietary intake, but because the body synthesizes palmitoleic acid, deficiency remains unlikely. Testing for palmitoleic acid is not standard in clinical practice, but fatty acid profiles in blood lipids can be assessed via specialized laboratory tests measuring non-esterified fatty acids or erythrocyte membrane composition. Reference ranges are not universally established, but some commercial lab sources suggest optimal circulating palmitoleic acid in adipose or erythrocyte lipids may be lower than 0.64 wt% in healthy adults. Interpretation of such results requires context with essential fatty acid status and overall lipid panels, and clinical significance is judged in conjunction with other metabolic markers such as fasting glucose, insulin sensitivity indices, and lipid profiles. In summary, while isolated deficiency of palmitoleic acid is uncommon, alterations in its levels may reflect changes in metabolic health and broader dietary patterns rather than a specific nutrient deficiency syndrome.

Because MUFA 16:1 c (palmitoleic acid) is a specific monounsaturated fatty acid, the foods highest in this nutrient tend to be fats, oils, and foods with higher fat content. According to nutrient ranking data from USDA-based tools, the foods richest in palmitoleic acid include nuts, fish, poultry with skin, and certain oils. Macadamia nuts and macadamia nut oil are among the most concentrated plant sources, with raw macadamia nuts containing over 3.6 grams of palmitoleic acid per ounce, making them a top dietary source. Eel and herring also provide significant amounts of palmitoleic acid among animal-derived foods. Avocado, particularly in pureed form, delivers nearly 1.9 grams per cup, illustrating that plant foods can contribute meaningful intake of this MUFA when consumed in larger servings. Other notable sources include chicken with skin and various fish oils. Chicken thigh with skin, for example, contains approximately 1.9 grams of palmitoleic acid per serving, and menhaden oil, a fish oil, contributes about 1.4 grams per tablespoon. Fish such as Atlantic salmon and sablefish provide substantial amounts of palmitoleic acid alongside other beneficial long-chain fatty acids. Additionally, processed meats like kielbasa sausage and pepperoni contain palmitoleic acid but should be consumed in moderation due to their higher sodium and saturated fat content. Plant oils such as avocado oil and macadamia oil are concentrated sources, with sea buckthorn oil also containing high palmitoleic acid percentages, although specific gram amounts per serving depend on the oil and preparation. Traditional dietary patterns that include MUFA-rich foods such as nuts, seeds, and certain fish align with evidence suggesting the benefits of unsaturated fats for heart health and metabolic regulation. While palmitoleic acid is just one component of total dietary fat, the foods listed here also provide other beneficial nutrients such as vitamin E, fiber (in plant sources), and omega-3 fatty acids (in fish sources), contributing to overall dietary quality. Incorporating a variety of these foods as part of a balanced diet can help ensure an adequate intake of MUFA 16:1 c along with other essential nutrients.

MUFA 16:1 c, like other dietary fatty acids, is absorbed in the small intestine through mechanisms common to long-chain fatty acids. After ingestion, dietary fats are emulsified by bile acids, facilitating the action of pancreatic lipases that hydrolyze triglycerides into free fatty acids and monoacylglycerols. These components are incorporated into micelles, which transport them to the intestinal mucosa for absorption. Enterocytes then re-esterify free fatty acids, including palmitoleic acid, into triglycerides and package them into chylomicrons for lymphatic transport and eventual entry into systemic circulation. Factors that enhance absorption of palmitoleic acid include the presence of bile acids and a mixed meal containing other fats, which stimulate bile release and pancreatic enzyme activity. The food matrix also influences bioavailability; for example, oils and nuts where the fatty acid is present in triglyceride form may be more readily absorbed compared to fatty acids bound within complex food structures. Conversely, malabsorption syndromes such as pancreatic insufficiency, cholestatic liver disease, or small intestinal mucosal damage can impair fat absorption, including palmitoleic acid, leading to steatorrhea and deficiencies in fat-soluble nutrients. Because palmitoleic acid is not an essential nutrient, impaired absorption does not produce a discrete deficiency syndrome, but it may reflect broader malabsorption issues requiring clinical evaluation. Interactions with other dietary components can affect the distribution and metabolism of palmitoleic acid. High intake of saturated fats and trans fats may compete for incorporation into chylomicrons and influence lipid profiles, whereas diets high in fiber can bind bile acids and potentially reduce fat absorption efficiency. Additionally, the endogenous synthesis of palmitoleic acid via stearoyl-CoA desaturase in adipose tissue and liver contributes to circulating levels independent of dietary absorption. Therefore, blood levels represent a combination of dietary intake and endogenous production, with implications for metabolic regulation. Understanding absorption and bioavailability is essential for interpreting circulating palmitoleic acid measurements and for designing dietary strategies aimed at modifying fatty acid profiles for metabolic health interventions.

Supplements containing palmitoleic acid, often marketed as "omega-7" products, have emerged in the nutraceutical market with claims of supporting metabolic health, insulin sensitivity, and anti-inflammatory effects. These supplements typically derive palmitoleic acid from plant oils such as macadamia or sea buckthorn or from marine sources with concentrated fatty acid profiles. However, because palmitoleic acid is not an essential nutrient with a defined dietary requirement, supplementation is not universally recommended and should be considered in the context of individual health goals and under professional guidance. Some small human intervention studies have evaluated the effects of supplemental palmitoleic acid on biomarkers of inflammation and metabolism, with doses ranging from approximately 200 to 1,000 mg per day. These trials have generally reported that palmitoleic acid supplements are well tolerated without major adverse effects, but evidence regarding significant clinical benefits remains limited and inconclusive. For example, while preclinical and observational research suggests potential roles in improving insulin sensitivity, reducing inflammatory markers, and supporting lipid metabolism, larger randomized controlled trials are sparse and results have not established definitive recommendations for supplementation. For individuals with specific metabolic concerns, such as elevated fasting glucose, insulin resistance, or chronic low-grade inflammation, a health professional may consider a trial of palmitoleic acid supplementation alongside established lifestyle interventions such as diet modification, physical activity, and weight management. Typical supplemental forms include oils standardized for palmitoleic acid content, often provided in softgel or liquid form. Given that palmitoleic acid is a fat, taking supplements with meals containing other dietary fats may enhance absorption and integration into lipid metabolism pathways. It is important to recognize that supplements should complement, not replace, a balanced diet rich in whole foods. Foods high in monounsaturated fats, including those containing palmitoleic acid, offer a matrix of nutrients that contribute to overall health beyond isolated fatty acids. Before starting any supplement, individuals should discuss potential benefits, appropriate dosages, and safety considerations with a healthcare provider, particularly those with underlying health conditions or those taking medications that could interact with fatty acid metabolism.

Because palmitoleic acid is not considered an essential nutrient with a defined tolerable upper intake level (UL), authoritative bodies such as the NIH Office of Dietary Supplements have not established toxicity thresholds. Available data from small human studies using supplemental palmitoleic acid in doses up to approximately 1,000 mg per day have not reported significant adverse events, suggesting that moderate supplemental intakes are generally safe for most adults when consumed with food and under supervision. However, the absence of a defined UL does not imply that very high intakes are without risk, particularly when consumed as highly concentrated supplements or isolated fatty acid preparations. Fatty acids, including palmitoleic acid, are integrated into complex lipid metabolic pathways, and excessive intake could theoretically disrupt lipid profiles or contribute to imbalances in fatty acid composition. For example, disproportionately high levels of certain fatty acids relative to others may influence membrane fluidity, lipid signaling, or the activity of desaturase enzymes involved in fatty acid metabolism. While specific toxicity symptoms attributable solely to palmitoleic acid overconsumption have not been well characterized, high intakes of fats in general can lead to gastrointestinal discomfort, increased caloric load, and potential weight gain if not balanced within total energy requirements. Given the lack of standardized toxicity data, individuals considering supplemental palmitoleic acid should do so at doses informed by research studies (e.g., 200–1,000 mg per day) and under the guidance of a clinician. Monitoring of lipid panels, liver function tests, and markers of glucose metabolism can help assess the impact of supplementation and ensure safety. It is also important to consider the source of palmitoleic acid; supplements derived from whole oils may contain additional nutrients that influence health outcomes, whereas isolated fatty acid preparations may lack these components. As with all nutrients and bioactive compounds, moderation and context within the overall dietary pattern are key to minimizing potential adverse effects and optimizing health benefits.

While specific interactions between MUFA 16:1 c (palmitoleic acid) and prescription medications are not extensively documented, the fatty acid’s influence on metabolic pathways suggests possible indirect interactions with drugs affecting lipid and glucose metabolism. Palmitoleic acid has been studied for its effects on insulin sensitivity, glucose uptake, and lipid handling, which may interact with medications prescribed for diabetes and dyslipidemia. For example, insulin sensitizers such as metformin or thiazolidinediones modulate insulin signaling pathways that palmitoleic acid may influence as a lipokine; although no direct contraindications have been established, concurrent use of palmitoleic acid supplements with these medications could theoretically alter glucose metabolism and warrants monitoring of blood glucose levels. Similarly, palmitoleic acid’s potential effects on lipid profiles suggest that individuals taking statins or other lipid-lowering agents should discuss supplement use with their healthcare provider. Statins and fibrates modulate cholesterol synthesis and triglyceride levels, and changes in fatty acid intake can influence lipid panels. While adjusting dietary fat intake is a common strategy for managing dyslipidemia, introducing concentrated palmitoleic acid supplements may affect lipid fractions and should be evaluated in context with pharmacotherapy goals. Because palmitoleic acid is absorbed through the same pathways as other dietary fats, concurrent use with orlistat, a lipase inhibitor used for weight management, may reduce its absorption and efficacy. Additionally, bile acid sequestrants prescribed for hyperlipidemia can bind dietary fats and fat-soluble vitamins, potentially reducing palmitoleic acid absorption when taken together. For individuals on anticoagulant therapy such as warfarin, changes in dietary fat intake can influence vitamin K absorption and lipid profiles, although direct interactions with palmitoleic acid have not been documented. Overall, while palmitoleic acid does not have widely recognized drug interactions, individuals on medications for metabolic conditions should consult healthcare providers before initiating supplements. Close monitoring of drug efficacy, metabolic markers, and potential side effects can help ensure safe and effective integration of dietary strategies with pharmacological treatments.

Common Forms: Concentrated palmitoleic acid oil capsules, Sea buckthorn oil supplements, Macadamia oil softgels

Typical Doses: 200–1,000 mg/day in research settings

When to Take: With meals to enhance absorption

Best Form: Oil form taken with a meal

⚠️ Interactions: Metformin, Statins, Orlistat